




About Genmab

Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab's science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Our Strengths & Differentiators

- World-Class antibody biology knowledge and deep insight into disease targets
- Discovery and development engine with proprietary technologies that allow us to build a world-class pipeline
- In-house expertise with solid track record of building successful strategic partnerships
- Pipeline of potential best-in-class and first-in-class therapies
- Experienced, diverse leadership team


How we Operate



Genmab's Growing Organization & Presence



2025 Financials (USD)



Our Purpose

Our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics

Our Vision

By 2030, our KYSO antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases

Our Values

- Passion for Innovation
- Determined - being the best at what we do
- Integrity - we do the right thing
- We work as one team & respect each other

Our Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable and successful biotech

*Operating Expenses exclude 2025 charges related to: 1) acquisition and integration-related charges of \$185 million and 2) amortization of intangible assets acquired through acquisitions of \$13 million.

Innovative Pipeline: Genmab owned products $\geq 50\%$

Program	Dev. by	Clinical Phase			
		1	2	3	Regulatory Approval*
Epcoritamab (EPKINLY®/TEPKINLY®)	Genmab/AbbVie	█	█	█	█
Tisotumab vedotin (Tivdak®)	Genmab/Pfizer	█	█	█	█
Rinatabart sesutecan (Rina-S®)	Genmab	█	█	█	
Petosemtamab	Genmab	█	█	█	
GEN1059 (BNT314)	Genmab/BioNTech	█			
GEN1057	Genmab	█			
GEN3018	Genmab	█			
GEN1079	Genmab	█			

*See local prescribing information for full indications/safety information

Royalty Portfolio

DARZALEX® /DARZALEX FASPRO®, RYBREVAANT®/ RYBREVAANT FASPRO®, TECVAYLI®, and TALVEY® discovered and/or developed & marketed by J&J

Kesimpta® developed & marketed by Novartis

TEPEZZA® developed & marketed by Amgen

BIZENGRI®, part of Genmab's acquisition of Merus, exclusively licensed in the US to Partner Therapeutics, Inc.

Amlenetug, in development by Lundbeck

Mim8 (denecimig), in development by Novo Nordisk

>45 Cumulative INDs since 1999

Created by Genmab or with Genmab's technologies

Proprietary Technologies Allow us to Build a World-class Pipeline

DuoBody® Platform

- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases and hemophilia
- Multiple commercial & research collaborations

HexaBody® Platform

- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

DuoHexaBody® Platform

- Antibody technology that combines **DuoBody** and **HexaBody** platforms
- Creates bispecific antibodies with target mediated enhanced potency

HexElect® Platform

- Antibody technology platform inspired by **HexaBody** platform
- Combines dual targeting with enhanced selectivity & potency

Acquisitions

- With our acquisition of ProfoundBio we gained novel ADC technology platforms.
- We gained additional proprietary technology platforms as part of our acquisition of Merus

This document contains forward looking statements that involve significant risks and uncertainties. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. February 17, 2026